

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4854892

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RASNA THERAPEUTICS LIMITED	03/01/2018
RECEIVING PARTY DATA	
Name:	RASNA RESEARCH INC.
Street Address:	420 LEXINGTON AVENUE
Internal Address:	SUITE 2525
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10170
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	62394104
Application Number:	62444330
Application Number:	62500459
Application Number:	15703953
PCT Number:	US2017051427
CORRESPONDENCE DATA	
Fax Number:	(617)937-2400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 937-2473
Email:	fvandermaelen@cooley.com
Correspondent Name:	COOLEY LLP, ATTN: PATENT GROUP
Address Line 1:	1299 PENNSYLVANIA AVENUE, NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	RASN-007
NAME OF SUBMITTER:	THOMAS J. PAXTON
SIGNATURE:	/Thomas J. Paxton/
DATE SIGNED:	03/07/2018

Total Attachments: 5

source=Rasna Assignment#page1.tif

source=Rasna Assignment#page2.tif

source=Rasna Assignment#page3.tif

source=Rasna Assignment#page4.tif

source=Rasna Assignment#page5.tif

ASSIGNMENT

WHEREAS, Rasna Therapeutics Limited, a corporation having its principal place of business at **Mayfair, London, United Kingdom W1K 1DG** (the "Assignor") is the owner of invention(s) (the "Invention(s)") set forth in the application(s) for patent identified in Appendix A.

WHEREAS, Rasna Research Inc., a corporation having its principal place of business at **420 Lexington Avenue, Suite 2525, New York, New York 10170** its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified in Appendix A; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).


The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.


The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.


Date: 03/01/2018

By: 
Name: TIZIANO LAZZARETTI
Title: CFO
Company: Rasna Therapeutics Limited

Witness Signature: 

Date: 02 MARCH 2018


Print Witness Name: HANA MALIK

Witness Signature: 


Date: 02 MARCH 2018

Print Witness Name: BARBARA ZILOVI

Date: 03/01/2018

By: 
Name: Kunwar Shaitabhai
Title: CEO
Company: Rasna Research Inc.

Witness Signature:  Date: March 01, 2018
Print Witness Name: VASEEM PALEJWALA

Witness Signature:  Date: 01 MARCH 2018
Print Witness Name: JULES JACOB

Appendix A

1. U.S Application No. 62/394,104, filed 9/13/2016
2. U.S. Application No. 62/444,330, filed 1/9/2017
3. U.S. Application No. 62/500,459, filed 5/2/2017
4. U.S. Application No. 15/703,953, filed 9/13/2017
5. PCT Application No. PCT/US2017/051427, filed 9/13/2017

154124654 v1